A clinical case definition and guidelines for medical practitioners

An overview of the canadian consensus document


Loebel M, Grabowski P, Heidecke H, Bauer S, Hanitsch LG, Wittke K, Meisel C, Reinke P, Volk HD, Fluge Ø, Mella O. Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. Brain, Behavior, and Immunity. 2016 Feb 29;52:32-9.

Rowe PC, Barron DF, Calkins H, Maumenee IH, Tong PY, Geraghty MT. Orthostatic intolerance and chronic fatigue syndrome associated with Ehlers-Danlos syndrome. The Journal of pediatrics. 1999 Oct 31;135(4):494-9.

Castori M, Morlino S, Celletti C, Celli M, Morrone A, Colombi M, Camerota F, Grammatico P. Management of pain and fatigue in the joint hypermobility syndrome (aka Ehlers–Danlos syndrome, hypermobility type): principles and proposal for a multidisciplinary approach. American Journal of Medical Genetics Part A. 2012 Aug 1;158(8):2055-70.

Celletti C, Galli M, Cimolin V, Castori M, Albertini G, Camerota F. Relationship between fatigue and gait abnormality in joint hypermobility syndrome/Ehlers-Danlos syndrome hypermobility type. Research in developmental disabilities. 2012 Dec 31;33(6):1914-8.

Castori M, Morlino S, Celletti C, Ghibellini G, Bruschini M, Grammatico P, Blundo C, Camerota F. Re‐writing the natural history of pain and related symptoms in the joint hypermobility syndrome/Ehlers–Danlos syndrome, hypermobility type. American Journal of Medical Genetics Part A. 2013 Dec 1;161(12):2989-3004.

Scheper MC, de Vries JE, Verbunt J, Engelbert RH. Chronic pain in hypermobility syndrome and Ehlers–Danlos syndrome (hypermobility type): it is a challenge. Journal of pain research. 2015;8:591.

Chopra P., Low Dose Naltrexone and chronic pain


The intractable pain patients guide to pain free hours


TENNANT, Forest; HERMANN, Laura. Normalization of serum cortisol concentration with opioid treatment of severe chronic pain. Pain Medicine, 2002, 3. Jg., Nr. 2, S. 132-134.

VADIVELU, Nalini, et al. Role of ketamine for analgesia in adults and children. Journal of Anaesthesiology, Clinical Pharmacology, 2016, 32. Jg., Nr. 3, S. 298.

CASTORI, Marco. Pain in Ehlers-Danlos syndromes: manifestations, therapeutic strategies and future perspectives. Expert Opinion on Orphan Drugs, 2016, 4. Jg., Nr. 11, S. 1145-1158.

ARFÈ, Andrea, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. bmj, 2016, 354. Jg., S. i4857.

JANAKIRAMAN, Raguraman; HAMILTON, Laura; WAN, Aston. Unravelling the efficacy of antidepressants as analgesics. Australian family physician, 2016, 45. Jg., Nr. 3, S. 113-117.

YOUNGER, Jarred; PARKITNY, Luke; MCLAIN, David. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical rheumatology, 2014, 33. Jg., Nr. 4, S. 451-459.

GHAI, Babita, et al. Off-Label, Low-Dose Naltrexone for Refractory Chronic Low Back Pain. Pain Medicine, 2014, 15. Jg., Nr. 5, S. 883-884.

ORBAI, Ana-Maria; MEYERHOFF, John O. The effectiveness of tricyclic antidepressants on lumbar spinal stenosis. Bulletin of the NYU hospital for joint diseases, 2010, 68. Jg., Nr. 1, S. 22.